CAS Number63590-64-7
SynonymsTerazosin Hydrochloride; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone; MFCD00467965
Molecular FormulaC19H25O4N5
Molecular Weight387.44
Purity98%
Density1.332 g/cm3
Boiling Point664.5ºC at 760 mmHg
Melting Point281-283°C
Appearancepowder
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 63590-64-7 |
| Catalog No. | 2A-9012633 |
| Chinese Name | 特拉唑嗪 |
| Synonyms | Terazosin Hydrochloride; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone; MFCD00467965 |
| Molecular Formula | C19H25O4N5 |
| Molecular Weight | 387.44 |
| Purity | 98 |
| Density | 1.332 g/cm3 |
| Boiling Point | 664.5ºC at 760 mmHg |
| Melting Point | 281-283°C |
| Appearance | powder |
| Water Solubility | H2O: 25 mg/mL |
| Storage Condition | -20°C Freezer |
| Application | Terazosin is a selective antagonist of α-1 adrenergic receptors and can act on benign prostatic hyperplasia. |
| MDL Number | MFCD00072144 |
| SMILES | COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC |
| InChI | InChI=1S/C19H25N5O4.ClH/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14;/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22);1H |
| InChI Key | VCKUSRYTPJJLNI-UHFFFAOYSA-N |
| Hazard Symbols | Transport |
| MSDS | msds/12633_1_63590_64_7.pdf |
| Bioactivity | Terazosin is a selective alpha1-antagonist used for treatment of symptoms of benign prostatic hyperplasia (BPH).Target: Alpha-1 Adrenergic ReceptorTerazosin is selective for alpha 1A-adrenoceptors which appear to dominate in the human prostate; the therapeutic relevance of this selectivity remains to be assessed in clinical studies [1]. Administration of terazosin 1 mg orally for 28 d. Terazosin initially shifted the dose-response curve of phenylephrine to the right, with a significant increase in ED50 for phenylephrine from a control value of 102 to 759 ng/min on day 1 of terazosin (P < 0.001). The mean Kd of terazosin was estimated as 11 ± 15 nM in the first few days of treatment. This study demonstrates that pharmacological tolerance to the alpha 1-adrenoceptor blocking action of terazosin occurs in man and may be responsible for loss in efficacy with chronic therapy [2]. Related Catalog Signaling Pathways >> GPCR/G Protein >> Adrenergic Receptor Natural Products >> Alkaloid Research Areas >> Metabolic Disease References [1]. Michel, M.C., et al., Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol, 1996. 16(1): p. 21-8. [2]. Vincent, J., et al., Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazosin in humans. J Clin Invest, 1992. 90(5): p. 1763-8. Chemical & Physical Properties Density 1.332 g/cm3 Boiling Point 664.5ºC at 760 mmHg Melting Point 281-283°C Molecular Formula C19H25N5O4 Molecular Weight 387.43300 Flash Point 355.7ºC Exact Mass 387.19100 PSA 103.04000 LogP 1.64090 InChIKey VCKUSRYTPJJLNI-UHFFFAOYSA-N SMILES COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC Storage condition -20°C Freezer Water Solubility H2O: 25 mg/mL |
| Use of | Properties Articles35 Name terazosin Synonym More Synonyms Terazosin Biological Activity Related Catalog Signaling Pathways >> GPCR/G Protein >> Adrenergic Receptor Natural Products >> Alkaloid Research Areas >> Metabolic Disease References [1]. Michel, M.C., et al., Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol, 1996. 16(1): p. 21-8. [2]. Vincent, J., et al., Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazosin in humans. J Clin Invest, 1992. 90(5): p. 1763-8. Chemical & Physical Properties Molecular Formula C19H25N5O4 Exact Mass 387.19100 PSA 103.04000 LogP 1.64090 InChIKey VCKUSRYTPJJLNI-UHFFFAOYSA-N |
| Transport Info | Shipping Name: UN |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.2 United Nations shipping name European Land Transport Dangerous Regulations: Non-dangerous goods IMDG Code: Non-dangerous goods International air transport dangerous goods regulations: non-dangerous goods 14.3 Transport hazard categories European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.4 Package group European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.5 Environmental hazards European Land Transport Danger Regulations: No International Maritime Danger Regulations International Air Transport Danger Regulations: No Marine pollutants (yes/no): No 14.6 Special reminder to users No data available |
| Related Products in API & Advanced Intermediates | ||
|---|---|---|
| Tecloftalam metabolite | 26491-30-5 | 2A-9012603 |
| Telmisartan | 144701-48-4 | 2A-9012611 |
| Tenofovir | 147127-20-6 | 2A-9012625 |
| Tenofovir disoproxil | 202138-50-9 | 2A-9012626 |
| Gatifloxacin | 112811-59-3 | 2A-9012631 |
| Terazosin hydrochloride | 63074-08-8 | 2A-9012634 |
| Timolol | 26839-75-8 | 2A-9012729 |
| Tiotropium bromide | 136310-93-5 | 2A-9012740 |
| Tiotropium bromide hydrate | 139404-48-1 | 2A-9012741 |
| Tipranavir | 17484-41-4 | 2A-9012744 |
| Browse all API & Advanced Intermediates products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS